ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 386

Idiopathic Granulomatous Mastitis: The Role of Rheumatologists in Treating This Rare Cause of Breast Pain

Sarah Ringsted1 and Marcia Friedman 1, 1Oregon Health and Science University, Portland, OR

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: methotrexate (MTX)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: Miscellaneous Rheumatic & Inflammatory Disease Poster I: Fibroinflammatory & Granulomatous Disorders & Therapies

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose:

Idiopathic granulomatous mastitis (IGM) is an inflammatory breast disease occurring primarily in young to middle-aged women (1, 2). IGM typically presents with a tender, firm breast mass that may be accompanied by redness, irritation, and drainage. The diagnosis of IGM is made by breast biopsy showing non-caseating granuloma after other causes of granulomatous mastitis have been excluded (1, 4). IGM is a poorly understood disease; there is no consensus regarding underlying cause, risk factors, and optimal treatment of this condition (3). However, IGM is being increasingly recognized as an inflammatory condition and referred to rheumatologists to aid in immunomodulatory management. IGM is primarily managed by breast surgeons and most of our understanding about this disease comes from surgical literature. However, a growing body of evidence, including this case series, suggests that IGM is a systemic inflammatory disease, and that rheumatologists are important and well situated to help care for these patients.

Methods:

IGM patients were identified via the OHSU Cohort Discovery tool who carried a diagnosis of “granulomatous mastitis”. 30 patients seen between 2007-2018 where identified. Retrospective chart review was used to verify that IGM diagnosis was accurate, collect data on baseline characteristics, clinical features and treatment course/outcomes. 2 patients were excluded (1 diagnosed with alternative condition and 1 without adequate follow-up).

Results:

Of the 28 IGM patients, all were female, the mean age was 32, the majority (60.7%) were Hispanic. The mean follow-up was 27 months and 17% of patients were treated by rheumatologists. Consistent with previous reports, the majority of patients had a history of pregnancy (93%) and breastfeeding (92%). Interestingly, 4 patients had inflammatory arthritis/arthralgias and 5 had erythema nodosum. 23 patients had adequate follow-up to assess treatment response. Treatment groups were divided into surgery plus high dose steroids (n=3), high dose steroids alone (n=12), methotrexate (MTX) and high dose steroids (+/- surgery) (n=3) and other (n=5). A rheumatologist saw all patients who received MTX. 7 patients (30%) had disease relapse after initial treatment and 4 patients (17%) had persistent disease. The highest rates of relapse were in the steroids alone group (42%) and lowest rate of relapse was in the methotrexate group (0%). Overall, 83% of patients eventually achieved a disease free remission with post-remission follow-up of over 1 year in 74%.

Conclusion:

This case series of 28 IGM patients suggests that MTX in combination with high dose steroids may successfully treat IGM, although larger prospective studies are needed.  We also report a higher incidence of arthritis/arthralgia and erythema nodosum than previously described—it is possible that these systemic findings are more likely to be recognized by a rheumatologist. IGM is an inflammatory disease and a rheumatologist is a valuable addition to the treatment team for IGM patients.


IGM Table 1

Table 1: Baseline Characteristics of 28 patients with Idiopathic Granulomatous Mastitis


IGM Table 2

Table 2: Clinical Features of Idiopathic Granulomatosis Mastitis at Time of Diagnosis in 28 Patients


IGM Table 3

Table 3: Idiopathic Granulomatous Mastitis Treatment Outcomes in 23 patients


Disclosure: S. Ringsted, None; M. Friedman, None.

To cite this abstract in AMA style:

Ringsted S, Friedman M. Idiopathic Granulomatous Mastitis: The Role of Rheumatologists in Treating This Rare Cause of Breast Pain [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/idiopathic-granulomatous-mastitis-the-role-of-rheumatologists-in-treating-this-rare-cause-of-breast-pain/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/idiopathic-granulomatous-mastitis-the-role-of-rheumatologists-in-treating-this-rare-cause-of-breast-pain/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology